文献速递慢性肾脏病血液净化与透析

CREDENCE 试验中消除 eGFR 计算中黑人种族系数可能产生的影响

Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial.
PubMed 文献 · Clin J Am Soc Nephrol · 2022-01-21

在 CREDENCE 试验中,用不含种族系数的 2009 CKD-EPI 肌酐方程重新计算 eGFR 会排除 22 例(10%)已随机化的黑人受试者(eGFR<30 ml/min per 1.73 m2),用 2021 CKD-EPI 方程会排除 8 例(4%)黑人受试者(低 eGFR)和 1 例(0.4%)黑人受试者(eGFR≥90 ml/min per 1.73 m2)。重新计算后心血管和肾脏治疗效应在各 eGFR 类别中保持一致,但卡格列净对 eGFR 慢性变化的影响在黑人受试者中减弱 7%,在非黑人受试者中增加 6%。

要点

  • 用无种族系数的 2009 CKD-EPI 方程重新计算 eGFR 会排除 22 例(10%)已随机化的黑人受试者(eGFR<30 ml/min per 1.73 m2)。
  • 用 2021 CKD-EPI 方程重新计算会排除 8 例(4%)黑人受试者(低 eGFR)和 1 例(0.4%)黑人受试者(eGFR≥90 ml/min per 1.73 m2)。
  • 重新计算后心血管和肾脏治疗效应在各 eGFR 类别中保持一致,但卡格列净对 eGFR 慢性变化的影响在黑人受试者中减弱 7%,在非黑人受试者中增加 6%。

核心结论

  • 在 CREDENCE 试验中,不含种族系数重新计算 eGFR 对事件率和黑人受试者相对比例有小的但可能重要的影响,而未大幅改变疗效估计。

研究设计与样本

  • 对 CREDENCE 试验(将 2 型糖尿病和 CKD 个体随机分配至卡格列净或安慰剂)受试者的纳入和结局进行评估,分别用 2009 CKD-EPI 肌酐方程(含或不含种族特异性系数)或 2021 CKD-EPI 肌酐方程计算 eGFR。
  • 共 4401 例随机化受试者,其中白人 2931 例(67%)、黑人 224 例(5%)、亚洲人 877 例(20%)、其他种族 369 例(8%)。
  • 使用比例风险模型和分段线性混合效应模型估计治疗效果和 eGFR 斜率。

主要发现

  • 用不含种族特异性系数的 2009 方程重新计算筛查 eGFR 对非黑人受试者满足纳入标准的可能性无影响,但会因 eGFR<30 ml/min per 1.73 m2 排除 22 例(10%)已随机化的黑人受试者。
  • 用 2021 方程重新计算会因低 eGFR 排除 8 例(4%)黑人受试者,因 eGFR≥90 ml/min per 1.73 m2 排除 1 例(0.4%)黑人受试者;非黑人受试者中分别有 30 例(0.7%)和 300 例(7%)因低 eGFR 和高 eGFR 被排除。
  • 黑人受试者中高比例(22 例中 8 例;36%)的终点事件发生在用无种族系数的 2009 方程重新计算后会被排除的个体中,而用 2021 方程重新计算时该比例为 8 例中 1 例(13%)。
  • 用任一方程重新计算后,心血管和肾脏治疗效应在各 eGFR 类别中保持一致;对 eGFR 斜率的估计治疗效应变化不大,但用 2021 方程重新计算后定性上更大。
  • 卡格列净对 eGFR 慢性变化的影响在黑人受试者中减弱 7%,在非黑人受试者中增加 6%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The effect of including race in the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation on screening, recruitment, and outcomes of clinical trials is unclear. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The inclusion and outcomes of participants in the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial, which randomized individuals with type 2 diabetes and CKD to canagliflozin or placebo, were evaluated after calculating eGFR using the 2009 CKD-EPI creatinine equation with and without a race-specific coefficient or the 2021 CKD-EPI creatinine equation. Treatment effects were estimated using proportional hazards models and piecewise linear mixed effects models for eGFR slope. RESULTS: Of 4401 randomized participants, 2931 (67%) were White participants, 224 (5%) were Black participants, 877 (20%) were Asian participants, and 369 (8%) participants were other race. Among randomized participants, recalculation of screening eGFR using the 2009 equation without a race-specific coefficient had no effect on the likelihood of non-Black participants meeting inclusion criteria but would have excluded 22 (10%) randomized Black participants for eGFR<30 ml/min per 1.73 m2. Recalculation with the 2021 equation would have excluded eight (4%) Black participants for low eGFR and one (0.4%) Black participant for eGFR≥90 ml/min per 1.73 m2, whereas 30 (0.7%) and 300 (7%) non-Black participants would have been excluded for low and high eGFR, respectively. A high proportion (eight of 22; 36%) of end points in Black participants occurred in individuals who would have been excluded following recalculation using the race-free 2009 equation but not when recalculated with the 2021 equation (one of eight; 13%). Cardiovascular and kidney treatment effects remained consistent across eGFR categories following recalculation with either equation. Changes in estimated treatment effects on eGFR slope were modest but were qualitatively larger following recalculation using the 2021 equation. However, the effect of canagliflozin on chronic change in eGFR was attenuated by 7% among Black participants and increased 6% in non-Black participants. CONCLUSIONS: In the CREDENCE trial, eGFR recalculation without the race-specific coefficient had small but potentially important effects on event rates and the relative proportion of Black participants without substantially changing efficacy estimates. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), NCT02065791.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Charytan DM, Yu J, Jardine MJ, et al. Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial. Clin J Am Soc Nephrol. 2022. PMID: 35063969. doi:10.2215/CJN.08980621

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。